Charles F. Davis

A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.

A Fowler, G Smith, R. Redfield, 1991, The New England journal of medicine.

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

R. Redfield, C. Tacket, D. Birx, 2000, The Journal of infectious diseases.